Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (1567)	2/11/1999 10:02:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 2135

<< I know is that Bristol Myers after 3 years isnt spending one more cent..Thats all I need to know>> I think that you are playing in the wrong sector.

To: Anthony@Pacific who wrote (1567)	2/11/1999 10:13:00 PM
From: Dave Gore	Read Replies (1) \| Respond to of 2135

Wrong! They never said THAT in the release, either..Anthony, you are losing respect fast ....geese, man....LOL AGAIN.... from the BMY NEWS RELEASE: "Under their revised agreement.... Bristol-Myers Squibb has the option to "reassume" development and marketing once proof that the protein meets its criteria for clinical trials becomes clear." Sounds to me that BMY wanted a revised agreement that keeps all their options open, huh?